1 HER2-positive breast cancer is aggressive, however, and the prognosis for patients with advanced disease at diagnosis or for those who are resistant to trastuzumab-based regimens remains poor.1,2 During a recent OncLive Peer Exchange®, experts in breast cancer research expressed optimism that ...
Towards personalized treatment for early stage HER2-positive breast cancer Article 13 December 2019 Main The discovery of the human epidermal growth factor receptor 2 (HER2) (King et al, 1985; Schechter et al, 1985), its association with poor prognosis in breast cancer (Slamon et al, 1987...
Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancerDisease outcomes of HER2+ breast cancers have dramatically improved after targeted therapies, such as trastuzumab became available. The main mechanism of action of trastuzumab depends on immunoactivation, while ...
HER2-Positive Breast Cancer: Update on Breast Cancer International Research Group Trials 来自 Semantic Scholar 喜欢 0 阅读量: 41 作者:JM Nabholtz,DM Reese,MA Lindsay,A Riva 摘要: HER2 gene amplification occurs in approximately 20% of primary breast cancers and is associated with a poor prognosis...
with metastaticHER2-positive breast cancer-aform of breast cancer that exhibits amplification of the gene encoding [...] chinese.eurekalert.org chinese.eurekalert.org 转移性人类上皮生长因子受体2(HER2)阳性乳腺癌——这是一种表现为人类上皮生长因子受体2(HER2)编码的基因扩增的乳腺癌——的病人常常出现肿...
HER2-positivebreastcancer46her2阳性乳腺癌 系统标签: breastpositive乳腺癌trastuzumab阳性pertuzumab Series.thelancetPublishedonlineDecember6,2016http://dx.doi/10.1016/S0140-6736(16)32417-51Breastcancer2HER2-positivebreastcancerSibylleLoibl,LucaGianniAnti-HER2treatmentforHER2-positivebreastcancerhaschangedthenatural...
Approximately 15–20% of human epidermal growth factor receptor 2 (HER2) is amplified and/or overexpressed in breast cancer [5]. HER2-positive BRCA is highly invasive, with short disease-free survival and poor prognosis. The HER2 gene (also known as HER2/neu, c-erbB-2) is located at 17...
To date, there have not been great breakthroughs in immunotherapy for HER2 positive breast cancer (HPBC). This study aimed to build a risk model that might contribute to predicting prognosis and discriminating the immune landscape in patients with HPBC. We analyzed the tumor immune profile of HP...
内容提示: Serieswww.thelancet.com Published online December 6, 2016 http://dx.doi.org/10.1016/S0140-6736(16)32417-5 1Breast cancer 2HER2-positive breast cancerSibylle Loibl, Luca GianniAnti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease. This ...
The HER2 protein, which encourages the growth of cancer cells, is present in about 20% of all breast cancers. While HER2-positive breast cancers tend to be very aggressive, today the prognosis is generally very good, thanks to the introduction of HER2 inhibitors such as trastuzumab (brand name...